MXPA02006034A - Oral mucosal dosage forms of apomorphine. - Google Patents
Oral mucosal dosage forms of apomorphine.Info
- Publication number
- MXPA02006034A MXPA02006034A MXPA02006034A MXPA02006034A MXPA02006034A MX PA02006034 A MXPA02006034 A MX PA02006034A MX PA02006034 A MXPA02006034 A MX PA02006034A MX PA02006034 A MXPA02006034 A MX PA02006034A MX PA02006034 A MXPA02006034 A MX PA02006034A
- Authority
- MX
- Mexico
- Prior art keywords
- apomorphine
- dextran
- weight
- oral mucosal
- formulation
- Prior art date
Links
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 title abstract 3
- 229960004046 apomorphine Drugs 0.000 title abstract 3
- 239000002552 dosage form Substances 0.000 title 1
- 229920002307 Dextran Polymers 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
A pharmaceutical formulation for the prolonged release oral mucosal administration of apomorpine which comprises a therapeutically effective amount of apomorphine or a pharmaceutically acceptable salt or pro drug thereof in combination with a carrier comprising from about 10 percent by weight to about 95 percent by weight dextran, based upon the total weight of the formulation. In one embodiment of the invention, dextran having a molecular weight in the range between about 5000 Daltons and 100,000 Daltons is the sole component of the formulation for prolonging the release of the active drug component. In an alternative embodiment, a mixture of microcrystalline cellulose and dextran act as the components to prolong the release of apomorphine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47584499A | 1999-12-30 | 1999-12-30 | |
| PCT/US2000/034548 WO2001049292A1 (en) | 1999-12-30 | 2000-12-19 | Oral mucosal dosage forms of apomorphine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02006034A true MXPA02006034A (en) | 2004-08-23 |
Family
ID=23889387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02006034A MXPA02006034A (en) | 1999-12-30 | 2000-12-19 | Oral mucosal dosage forms of apomorphine. |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1242088A1 (en) |
| JP (1) | JP2004501065A (en) |
| CN (1) | CN1414853A (en) |
| AU (1) | AU2440901A (en) |
| BR (1) | BR0012822A (en) |
| CA (1) | CA2394297A1 (en) |
| CZ (1) | CZ20022245A3 (en) |
| HK (1) | HK1051315A1 (en) |
| HU (1) | HUP0400495A3 (en) |
| IL (1) | IL150034A0 (en) |
| MX (1) | MXPA02006034A (en) |
| NO (1) | NO20023190L (en) |
| PL (1) | PL366204A1 (en) |
| WO (1) | WO2001049292A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0202365D0 (en) | 2002-08-05 | 2002-08-05 | Pharmacia Ab | New formulation and use thereof |
| SE0302947D0 (en) | 2003-01-24 | 2003-11-07 | Magle Ab | A composition material for transmucosal delivery |
| EP1617823B1 (en) * | 2003-01-24 | 2019-01-09 | Nicachet AB | A pouch comprising a nicotine composition for transmucosal delivery |
| US8263121B2 (en) | 2004-04-14 | 2012-09-11 | Takeda Pharmaceutical Company Limited | Solid pharmaceutical preparation |
| GB0509317D0 (en) * | 2005-05-06 | 2005-06-15 | Clarke Anthony | Pharmaceutical formulation of apomorphine |
| ES2699077T3 (en) * | 2009-06-12 | 2019-02-07 | Sunovion Pharmaceuticals Inc | Sublingual Apomorphine |
| WO2020243538A1 (en) * | 2019-05-31 | 2020-12-03 | Primo Pharmatech Llc | Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0689438B1 (en) * | 1993-03-26 | 2003-06-04 | Franciscus Wilhelmus Henricus Maria Merkus | Pharmaceutical compositions for intranasal administration of apomorphine |
| GB9517062D0 (en) * | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
-
2000
- 2000-12-19 JP JP2001549660A patent/JP2004501065A/en not_active Withdrawn
- 2000-12-19 MX MXPA02006034A patent/MXPA02006034A/en unknown
- 2000-12-19 IL IL15003400A patent/IL150034A0/en unknown
- 2000-12-19 HU HU0400495A patent/HUP0400495A3/en unknown
- 2000-12-19 PL PL00366204A patent/PL366204A1/en not_active Application Discontinuation
- 2000-12-19 WO PCT/US2000/034548 patent/WO2001049292A1/en not_active Ceased
- 2000-12-19 BR BR0012822-8A patent/BR0012822A/en not_active IP Right Cessation
- 2000-12-19 AU AU24409/01A patent/AU2440901A/en not_active Abandoned
- 2000-12-19 EP EP00988174A patent/EP1242088A1/en not_active Withdrawn
- 2000-12-19 HK HK03101912.0A patent/HK1051315A1/en unknown
- 2000-12-19 CN CN00818098A patent/CN1414853A/en active Pending
- 2000-12-19 CZ CZ20022245A patent/CZ20022245A3/en unknown
- 2000-12-19 CA CA002394297A patent/CA2394297A1/en not_active Abandoned
-
2002
- 2002-07-01 NO NO20023190A patent/NO20023190L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1414853A (en) | 2003-04-30 |
| BR0012822A (en) | 2004-03-09 |
| CZ20022245A3 (en) | 2002-10-16 |
| IL150034A0 (en) | 2002-12-01 |
| HUP0400495A2 (en) | 2004-06-28 |
| HUP0400495A3 (en) | 2007-05-02 |
| CA2394297A1 (en) | 2001-07-12 |
| EP1242088A1 (en) | 2002-09-25 |
| HK1051315A1 (en) | 2003-08-01 |
| PL366204A1 (en) | 2005-01-24 |
| WO2001049292A1 (en) | 2001-07-12 |
| NO20023190L (en) | 2002-08-29 |
| NO20023190D0 (en) | 2002-07-01 |
| AU2440901A (en) | 2001-07-16 |
| JP2004501065A (en) | 2004-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE424810T1 (en) | A DELAYED-RELEASE TABLET CONTAINING A HYDROCOLLOID AND A CELLULOSE ETHER | |
| HUP0203870A2 (en) | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | |
| EA200401009A1 (en) | PRELIMINARY GELATINIZED STARCH IN COMPOSITION WITH CONTROLLED DELIVERY | |
| BG106251A (en) | Levodopa (carbidopa) entacapone pharmaceutical preparation | |
| NO20011502L (en) | Fentanyl composition for the treatment of acute pain | |
| DK0954314T3 (en) | Dosage forms for ameliorating male erectile dysfunction | |
| MY118371A (en) | Tetrahydrolipstatin containing compositions | |
| GEP20074208B (en) | Substituted amides active at the cannabinoid-1 receptor | |
| BR0115965A (en) | Pharmaceutical compositions for oral release of pharmacologically active agents | |
| WO2001085257A3 (en) | Opioid antagonist compositions and dosage forms | |
| EE05191B1 (en) | A pharmaceutical composition comprising tolterodine and its use | |
| ES2132170T3 (en) | COMPOSITION OF L-DOPA ESTERS. | |
| EA200400007A1 (en) | PHARMACEUTICAL COMPOSITION FOR THE EFFICIENT INTRODUCTION OF APOMORPHIN, 6aR - (-) - N-PROPYL-NORAPOMORPHIN, THEIR DERIVATIVES AND THEIR PROCEDURES | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| CA2360220A1 (en) | Oxadiazole compounds and compositions for delivering active agents | |
| AP1849A (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
| PL1608349T3 (en) | Oral delivery system comprising an antibacterial and an anti-inflammatory agent | |
| PT975348E (en) | STABILIZED TIBOLONE COMPOSITIONS | |
| MXPA02006034A (en) | Oral mucosal dosage forms of apomorphine. | |
| CA2135179A1 (en) | Pharmaceutical Compositions of Alkylsulphonamides 5HT1 Agonists for Rectal Administration | |
| BR0014440A (en) | Oral controlled release formulations | |
| BE2016C017I2 (en) | ||
| WO2003070153A3 (en) | Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives | |
| TW200505504A (en) | Saquinavir mesylate oral dosage form | |
| MXPA01003340A (en) | Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of lh-rh analogues. |